Poster PDF's

1. Centrally Located Breast Cancer Is More Aggressive in Bahraini Patients

2. Is Laterality in Breast Cancer Still Worth Studying? Local Experience in Bahrain

3. Gender Disparities in the National Institutes of Health Funding for Breast Cancer

4. Bacopaside: Exploring its Potential in Addressing Chemoresistance and Modulating Doxorubicin Accumulation in Triple-Negative Breast Cancer Cells

5. Predictors of Axillary Complete Pathologic Response in Hormone Receptor–Positive, HER2-Negative, Clinically Node-Positive Breast Cancer

6. Treatment Outcomes of the KEYNOTE-522 Regimen in an Ethnically Diverse Patient Population

7. Real-World Efficacy and Adverse Events of Neoadjuvant Immunotherapy in Early-Stage Triple-Negative Breast Cancer Patients: A Multicenter Experience

8. Using a Liquid Biopsy Mediated Approach for Determination of HER2 Amplification Status in Patient Samples

9. Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2- Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

10. Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

11. Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2- Breast Cancer: KEYNOTE-756

12. EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

13. The Cause and Eradication of Breast Cancer

14. Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2- Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

15. Concurrent Use of Abemaciclib and Radiation Therapy (RT) Among Patients With HR+, HER2- Metastatic Breast Cancer (MBC): Real-World Utilization and Safety

16. Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2-, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

17. TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Chemotherapy (CT) Plus Pembrolizumab in Patients (pts) With PD-L1–Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC)

18. Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer: Phase 1b Cohort

19. Efficacy, Safety, and Quality of Life with Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

20. Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2-) Metastatic Breast Cancer (mBC)

21. Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2- Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

22. Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

23. ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor-Positive (ER+), HER2-Negative (HER2-) Breast Cancer (BC)

24. Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2− Early Breast Cancer: a Discrete Choice Survey Study

25. Treatment Patterns and Clinical Outcomes Following Endocrine Resistance Among HER2-Low Metastatic Breast Cancer Patients — Retrospective Observational Study

26. Prediction of Chemotherapy Benefit by MammaPrint® in Patients With HR+HER2- Early-Stage Breast Cancer From Real-World Evidence Studies

27. CARDIAC-STAR: Prevalence of Cardiovascular (CV) Comorbidities in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast Cancer (mBC)

28. Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

29. ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor-Positive (ER+), HER2-Negative (HER2-) Locally Advanced or Metastatic Breast Cancer (mBC)

30. Datopotamab Deruxtecan (Dato-Dxd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative (HR+/HER2-) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

31. Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

32. Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple-Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study

33. MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX

34. How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards

35. Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS

36. MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

37. Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population-Level Provider Model

38. Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer

39. The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction: A Nationwide Study

40. Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis

41. A Case Series of Breast Sarcomas

42. Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery

43. Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction

44. Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients

45. Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma in situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?

46. Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature

47. Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?

48. The Era 'or Error' of Second Localization Procedures

49. The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study

50. Nipple Sparing Mastectomy With Immediate Lift Using Vertical Technique: Our Initial Experience

51. Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?

52. UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

53. The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma in Situ

54. The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients

55. Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer

56. Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2- Breast Cancer

57. Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice

58. Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients

59. Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients

60. Racial Disparities in Hospitalization Outcomes among Women with Metastatic Breast Cancer in the United States by Palliative Care Utilization

61. High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30

62. The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population

63. Choice Architecture Bias in Genetic Counseling of Patients with Breast Cancer

64. Empowering Medical Students to Deliver Breast Health Education: A Community-Based Initiative

65. Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices

66. A Comparative Analysis of Changes in Treatment Recommendation for Black and White Patients with Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Study

67. Disparities in Regional Anesthesia Block Acceptance for Mastectomy With Reconstruction Surgery in a Standardized Setting

68. Magnetic Tracer Increases Surgical Productivity and Reduces Time to Surgery When Compared With Standard Lymph Node Mapping Modalities

69. The Importance of Tri-Modality Therapy for de novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

70. Navigating Lymphedema: The Impact of Indocyanine Green Lymphography (ICG_L) on Personalized Therapy Outcomes in Patients With Breast Cancer (BC)

71. Utility of Performing Staging MRI in Breast Cancer Patients Over the Age of 75

72. A Novel Biosignature for Early-Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast-Conserving Surgery

73. Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk DCIS After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-year Ipsilateral Breast Recurrence (IBR) Rates

74. An Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of BB-1701, a Novel Antibody-Drug Conjugate (ADC) Targeting Human Epidermal Growth Factor Receptor 2 (HER2), in Previously Treated Patients With HER2-Positive (HER2+) or HER2-Low Unresectable or Metastatic Breast Cancer